Truist Financial Cuts OrthoPediatrics (NASDAQ:KIDS) Price Target to $28.00

OrthoPediatrics (NASDAQ:KIDS) had its target price lowered by stock analysts at Truist Financial from $34.00 to $28.00 in a report issued on Monday, Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price would suggest a potential upside of 3.59% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Friday, September 13th. JMP Securities reaffirmed a “market outperform” rating and set a $50.00 price objective on shares of OrthoPediatrics in a research note on Friday, September 13th.

OrthoPediatrics Trading Up 4.2 %

KIDS stock opened at $27.03 on Monday. The business’s 50-day moving average is $28.45 and its 200 day moving average is $30.11. OrthoPediatrics has a 12-month low of $23.10 and a 12-month high of $36.23. The stock has a market cap of $644.10 million, a price-to-earnings ratio of -28.16 and a beta of 1.17. The company has a current ratio of 4.90, a quick ratio of 1.96 and a debt-to-equity ratio of 0.03.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. OrthoPediatrics had a negative return on equity of 5.44% and a negative net margin of 14.35%. The firm had revenue of $52.80 million for the quarter, compared to analyst estimates of $52.40 million. On average, sell-side analysts anticipate that OrthoPediatrics will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In other news, General Counsel Daniel J. Gerritzen sold 10,000 shares of OrthoPediatrics stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $29.30, for a total transaction of $293,000.00. Following the transaction, the general counsel now owns 77,304 shares in the company, valued at $2,265,007.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 31.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Creative Planning raised its position in OrthoPediatrics by 15.4% in the third quarter. Creative Planning now owns 10,130 shares of the company’s stock valued at $275,000 after purchasing an additional 1,353 shares during the period. SG Americas Securities LLC raised its holdings in OrthoPediatrics by 113.5% in the 3rd quarter. SG Americas Securities LLC now owns 8,199 shares of the company’s stock valued at $222,000 after buying an additional 4,358 shares during the period. Deerfield Management Company L.P. Series C purchased a new stake in OrthoPediatrics in the 2nd quarter valued at about $203,000. AQR Capital Management LLC acquired a new position in OrthoPediatrics in the second quarter valued at about $223,000. Finally, Paradigm Capital Management Inc. NY boosted its stake in OrthoPediatrics by 8.0% during the second quarter. Paradigm Capital Management Inc. NY now owns 134,400 shares of the company’s stock worth $3,865,000 after buying an additional 10,000 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.